Cargando…

Dual B Cell Immunotherapy Is Superior to Individual Anti-CD20 Depletion or BAFF Blockade in Murine Models of Spontaneous or Accelerated Lupus

OBJECTIVE: To determine whether a combination of B cell depletion and BAFF blockade is more effective than monotherapy in treating models of spontaneous or accelerated systemic lupus erythematosus (SLE) in (NZB × NZW)F1 mice. METHODS: Clinical parameters such as disease progression–free survival, pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, WeiYu, Seshasayee, Dhaya, Lee, Wyne P, Caplazi, Patrick, McVay, Sami, Suto, Eric, Nguyen, Allen, Lin, Zhonghua, Sun, Yonglian, DeForge, Laura, Balazs, Mercedesz, Martin, Flavius, Zarrin, Ali A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2015
Materias:	Systemic Lupus Erythematosus
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4312898/ https://www.ncbi.nlm.nih.gov/pubmed/25303150 http://dx.doi.org/10.1002/art.38907

Ejemplares similares

Gene Expression and Pharmacodynamic Changes in 1,760 Systemic Lupus Erythematosus Patients From Two Phase III Trials of BAFF Blockade With Tabalumab
por: Hoffman, Robert W., et al.
Publicado: (2017)

B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial
por: Furie, Richard A, et al.
Publicado: (2022)

Blockade of Interferon‐γ Normalizes Interferon‐Regulated Gene Expression and Serum CXCL10 Levels in Patients With Systemic Lupus Erythematosus
por: Welcher, Andrew A., et al.
Publicado: (2015)

Long‐Term Impact of Belimumab on Health‐Related Quality of Life and Fatigue in Patients With Systemic Lupus Erythematosus: Six Years of Treatment
por: Strand, Vibeke, et al.
Publicado: (2019)

3D genome alterations in T cells associated with disease activity of systemic lupus erythematosus
por: Zhao, Ming, et al.
Publicado: (2023)

A CD8 T Cell/Indoleamine 2,3-Dioxygenase Axis Is Required for Mesenchymal Stem Cell Suppression of Human Systemic Lupus Erythematosus
por: Wang, Dandan, et al.
Publicado: (2014)

Association of FCGR3A and FCGR3B Copy Number Variations With Systemic Lupus Erythematosus and Rheumatoid Arthritis in Taiwanese Patients
por: Chen, Ji-Yih, et al.
Publicado: (2014)

Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis
por: Jayne, David, et al.
Publicado: (2022)

Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial
por: He, Jing, et al.
Publicado: (2020)

Novel Assays of Thrombogenic Pathogenicity in the Antiphospholipid Syndrome Based on the Detection of Molecular Oxidative Modification of the Major Autoantigen β(2)-Glycoprotein I
por: Ioannou, Yiannis, et al.
Publicado: (2011)

Distinct roles for complement in glomerulonephritis and atherosclerosis revealed in mice with a combination of lupus and hyperlipidemia
por: Lewis, Myles J, et al.
Publicado: (2012)

Lack of Effect of a Single Injection of Human C-Reactive Protein on Murine Lupus or Nephrotoxic Nephritis
por: Carlucci, Francesco, et al.
Publicado: (2010)

Oxidative Stress, T Cell DNA Methylation, and Lupus
por: Li, YePeng, et al.
Publicado: (2014)

Sifalimumab, a Human Anti–Interferon-α Monoclonal Antibody, in Systemic Lupus Erythematosus: A Phase I Randomized, Controlled, Dose-Escalation Study: A Phase I Randomized, Controlled, Dose-Escalation Study
por: Petri, Michelle, et al.
Publicado: (2013)

The Parasitic Worm Product ES-62 Targets Myeloid Differentiation Factor 88–Dependent Effector Mechanisms to Suppress Antinuclear Antibody Production and Proteinuria in MRL/lpr Mice
por: Rodgers, David T, et al.
Publicado: (2015)

Association of Systemic Lupus Erythematosus With Decreased Immunosuppressive Potential of the IgG Glycome
por: Vučković, Frano, et al.
Publicado: (2015)

Belimumab in systemic lupus erythematosus
por: Vilas-Boas, Andreia, et al.
Publicado: (2015)

Autoantibody‐Positive Healthy Individuals Display Unique Immune Profiles That May Regulate Autoimmunity
por: Slight‐Webb, Samantha, et al.
Publicado: (2016)

Sensitivity to Change and Minimal Important Differences of the LupusQoL in Patients With Systemic Lupus Erythematosus
por: McElhone, Kathleen, et al.
Publicado: (2016)

Mitochondrial Dysfunction in the Liver and Antiphospholipid Antibody Production Precede Disease Onset and Respond to Rapamycin in Lupus‐Prone Mice
por: Oaks, Zachary, et al.
Publicado: (2016)

What to Expect When Expecting With Systemic Lupus Erythematosus (SLE): A Population‐Based Study of Maternal and Fetal Outcomes in SLE and Pre‐SLE
por: Arkema, Elizabeth V., et al.
Publicado: (2016)

A Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis
por: Rovin, Brad H., et al.
Publicado: (2016)

Cumulative Corticosteroid Dose Over Fifty‐Two Weeks in Patients With Systemic Lupus Erythematosus: Pooled Analyses From the Phase III Belimumab Trials
por: van Vollenhoven, Ronald F., et al.
Publicado: (2016)

Study of Flare Assessment in Systemic Lupus Erythematosus Based on Paper Patients
por: Isenberg, D., et al.
Publicado: (2017)

Brief Report: A Randomized, Double‐Blind, Parallel‐Group, Placebo‐Controlled, Multiple‐Dose Study to Evaluate AMG 557 in Patients With Systemic Lupus Erythematosus and Active Lupus Arthritis
por: Cheng, Laurence E., et al.
Publicado: (2018)

Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus: Results of a Twenty‐Four–Week, Multicenter, Randomized, Double‐Blind, Placebo‐Controlled, Parallel‐Arm, Phase IIb Study
por: Merrill, Joan T., et al.
Publicado: (2018)

Efficacy and Safety of Subcutaneous Belimumab in Anti–Double‐Stranded DNA–Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus
por: Doria, A., et al.
Publicado: (2018)

Long‐Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus: A Continuation of a Seventy‐Six–Week Phase III Parent Study in the United States
por: Furie, Richard A., et al.
Publicado: (2018)

Efficacy of Epratuzumab, an Anti‐CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjögren's Syndrome: Post Hoc Analyses From the EMBODY Trials
por: Gottenberg, Jacques‐Eric, et al.
Publicado: (2018)

REDD1/autophagy pathway promotes thromboinflammation and fibrosis in human systemic lupus erythematosus (SLE) through NETs decorated with tissue factor (TF) and interleukin-17A (IL-17A)
por: Frangou, Eleni, et al.
Publicado: (2019)

Toll‐Like Receptor 9 Deficiency Breaks Tolerance to RNA‐Associated Antigens and Up‐Regulates Toll‐Like Receptor 7 Protein in Sle1 Mice
por: Celhar, Teja, et al.
Publicado: (2018)

Combined genetic and transcriptome analysis of patients with SLE: distinct, targetable signatures for susceptibility and severity
por: Panousis, Nikolaos I, et al.
Publicado: (2019)

Lupus-associated atypical memory B cells are mTORC1-hyperactivated and functionally dysregulated
por: Wu, Chunmei, et al.
Publicado: (2019)

Association of Blood Concentrations of Complement Split Product iC3b and Serum C3 With Systemic Lupus Erythematosus Disease Activity
por: Kim, Alfred H. J., et al.
Publicado: (2019)

Organ damage in patients treated with belimumab versus standard of care: a propensity score-matched comparative analysis
por: Urowitz, Murray B, et al.
Publicado: (2019)

Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study
por: Hanly, John G., et al.
Publicado: (2019)

Low-density granulocytes activate T cells and demonstrate a non-suppressive role in systemic lupus erythematosus
por: Rahman, Saifur, et al.
Publicado: (2019)

Altered cognitive function in systemic lupus erythematosus and associations with inflammation and functional and structural brain changes
por: Barraclough, Michelle, et al.
Publicado: (2019)

Lupus nephritis is linked to disease-activity associated expansions and immunity to a gut commensal
por: Azzouz, Doua, et al.
Publicado: (2019)

Long‐Term Clinical Outcomes in a Cohort of Adults With Childhood‐Onset Systemic Lupus Erythematosus
por: Groot, N., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_uui8b53jch1ve0jls44aok2g9o